Does the media favor TARS or DSGN?

In the previous week, Tarsus Pharmaceuticals had 2 more articles in the media than Design Therapeutics. MarketBeat recorded 4 mentions for Tarsus Pharmaceuticals and 2 mentions for Design Therapeutics. Tarsus Pharmaceuticals' average media sentiment score of 1.60 beat Design Therapeutics' score of 0.94 indicating that Tarsus Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tarsus Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Design Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation and earnings, DSGN or KLRA?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Design Therapeutics N/A N/A -$69.79M -$1.20 N/A Kailera Therapeutics N/A N/A N/A N/A N/A

Is DSGN or KLRA more profitable?

Kailera Therapeutics' return on equity of 0.00% beat Design Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Design Therapeutics N/A -33.07% -31.29% Kailera Therapeutics N/A N/A N/A

Does the media favor DSGN or KLRA?

In the previous week, Design Therapeutics and Design Therapeutics both had 2 articles in the media. Kailera Therapeutics' average media sentiment score of 1.27 beat Design Therapeutics' score of 0.94 indicating that Kailera Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Design Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Kailera Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation and earnings, DSGN or IRON?

Disc Medicine is trading at a lower price-to-earnings ratio than Design Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Design Therapeutics N/A N/A -$69.79M -$1.20 N/A Disc Medicine N/A N/A -$212.18M -$6.62 N/A

Is DSGN or IRON more profitable?

Design Therapeutics' return on equity of -33.07% beat Disc Medicine's return on equity. Company Net Margins Return on Equity Return on Assets Design Therapeutics N/A -33.07% -31.29% Disc Medicine N/A -36.94% -33.88%

Does the media refer more to DSGN or IRON?

In the previous week, Disc Medicine had 18 more articles in the media than Design Therapeutics. MarketBeat recorded 20 mentions for Disc Medicine and 2 mentions for Design Therapeutics. Design Therapeutics' average media sentiment score of 0.94 beat Disc Medicine's score of 0.80 indicating that Design Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Design Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Disc Medicine 9 Very Positive mention(s) 2 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer NNNN or DSGN?

Design Therapeutics has a consensus price target of $16.50, suggesting a potential upside of 50.41%. Given Design Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Design Therapeutics is more favorable than Anbio Biotechnology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Anbio Biotechnology 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Design Therapeutics 1 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.88

Which has preferable earnings & valuation, NNNN or DSGN?

Anbio Biotechnology has higher revenue and earnings than Design Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Anbio Biotechnology $8.65M 259.33 $6.40M N/A N/A Design Therapeutics N/A N/A -$69.79M -$1.20 N/A

Is NNNN or DSGN more profitable?

Anbio Biotechnology's return on equity of 0.00% beat Design Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Anbio Biotechnology N/A N/A N/A Design Therapeutics N/A -33.07% -31.29%

Is ALMS or DSGN more profitable?

Design Therapeutics has a net margin of 0.00% compared to Alumis' net margin of -2,825.70%. Design Therapeutics' return on equity of -33.07% beat Alumis' return on equity. Company Net Margins Return on Equity Return on Assets Alumis -2,825.70% -88.79% -70.72% Design Therapeutics N/A -33.07% -31.29%

Does the media favor ALMS or DSGN?

In the previous week, Alumis had 1 more articles in the media than Design Therapeutics. MarketBeat recorded 3 mentions for Alumis and 2 mentions for Design Therapeutics. Design Therapeutics' average media sentiment score of 0.94 beat Alumis' score of 0.63 indicating that Design Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alumis 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Design Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Design Therapeutics (DSGN) Competitors

$10.97 +0.44 (+4.18%)

Closing price 06/12/2026 04:00 PM Eastern

Extended Trading

$10.96 -0.01 (-0.05%)

As of 06/12/2026 04:10 PM Eastern

Compare

DSGN vs. TARS, KLRA, IRON, NNNN, and ALMS

Should you buy Design Therapeutics stock or one of its competitors? MarketBeat compares Design Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Design Therapeutics include Tarsus Pharmaceuticals (TARS), Kailera Therapeutics (KLRA), Disc Medicine (IRON), Anbio Biotechnology (NNNN), and Alumis (ALMS). These companies are all part of the "pharmaceutical products" industry.

How does Design Therapeutics compare to Tarsus Pharmaceuticals?

Tarsus Pharmaceuticals (NASDAQ:TARS) and Design Therapeutics (NASDAQ:DSGN) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, risk, earnings, profitability, dividends, valuation and analyst recommendations.

Tarsus Pharmaceuticals presently has a consensus target price of $90.67, indicating a potential upside of 46.35%. Design Therapeutics has a consensus target price of $16.50, indicating a potential upside of 50.41%. Given Design Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Design Therapeutics is more favorable than Tarsus Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tarsus Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.78
Design Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

Tarsus Pharmaceuticals has higher revenue and earnings than Design Therapeutics. Tarsus Pharmaceuticals is trading at a lower price-to-earnings ratio than Design Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tarsus Pharmaceuticals	$451.36M	5.90	-$66.42M	-$1.14	N/A
Design Therapeutics	N/A	N/A	-$69.79M	-$1.20	N/A

Design Therapeutics has a net margin of 0.00% compared to Tarsus Pharmaceuticals' net margin of -9.02%. Tarsus Pharmaceuticals' return on equity of -14.19% beat Design Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tarsus Pharmaceuticals	-9.02%	-14.19%	-8.89%
Design Therapeutics	N/A	-33.07%	-31.29%

90.0% of Tarsus Pharmaceuticals shares are owned by institutional investors. Comparatively, 56.6% of Design Therapeutics shares are owned by institutional investors. 9.6% of Tarsus Pharmaceuticals shares are owned by company insiders. Comparatively, 17.1% of Design Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Tarsus Pharmaceuticals had 2 more articles in the media than Design Therapeutics. MarketBeat recorded 4 mentions for Tarsus Pharmaceuticals and 2 mentions for Design Therapeutics. Tarsus Pharmaceuticals' average media sentiment score of 1.60 beat Design Therapeutics' score of 0.94 indicating that Tarsus Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tarsus Pharmaceuticals	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Design Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Tarsus Pharmaceuticals has a beta of 0.49, indicating that its stock price is 51% less volatile than the broader market. Comparatively, Design Therapeutics has a beta of 1.63, indicating that its stock price is 63% more volatile than the broader market.

Summary

Tarsus Pharmaceuticals beats Design Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Design Therapeutics compare to Kailera Therapeutics?

Design Therapeutics (NASDAQ:DSGN) and Kailera Therapeutics (NASDAQ:KLRA) are both pharmaceutical products companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, earnings, media sentiment, valuation, dividends, profitability, risk and analyst recommendations.

Kailera Therapeutics' return on equity of 0.00% beat Design Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Design Therapeutics	N/A	-33.07%	-31.29%
Kailera Therapeutics	N/A	N/A	N/A

56.6% of Design Therapeutics shares are held by institutional investors. 17.1% of Design Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Design Therapeutics and Design Therapeutics both had 2 articles in the media. Kailera Therapeutics' average media sentiment score of 1.27 beat Design Therapeutics' score of 0.94 indicating that Kailera Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Design Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Kailera Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Design Therapeutics	N/A	N/A	-$69.79M	-$1.20	N/A
Kailera Therapeutics	N/A	N/A	N/A	N/A	N/A

Design Therapeutics currently has a consensus target price of $16.50, suggesting a potential upside of 50.41%. Kailera Therapeutics has a consensus target price of $42.75, suggesting a potential upside of 126.31%. Given Kailera Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Kailera Therapeutics is more favorable than Design Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Design Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
Kailera Therapeutics	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	3.00

Summary

Kailera Therapeutics beats Design Therapeutics on 5 of the 8 factors compared between the two stocks.

How does Design Therapeutics compare to Disc Medicine?

Design Therapeutics (NASDAQ:DSGN) and Disc Medicine (NASDAQ:IRON) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, dividends, earnings, valuation, institutional ownership, profitability, analyst recommendations and media sentiment.

Design Therapeutics currently has a consensus price target of $16.50, suggesting a potential upside of 50.41%. Disc Medicine has a consensus price target of $105.30, suggesting a potential upside of 54.88%. Given Disc Medicine's higher probable upside, analysts clearly believe Disc Medicine is more favorable than Design Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Design Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
Disc Medicine	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75

In the previous week, Disc Medicine had 18 more articles in the media than Design Therapeutics. MarketBeat recorded 20 mentions for Disc Medicine and 2 mentions for Design Therapeutics. Design Therapeutics' average media sentiment score of 0.94 beat Disc Medicine's score of 0.80 indicating that Design Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Design Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Disc Medicine	9 Very Positive mention(s)	2 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

56.6% of Design Therapeutics shares are owned by institutional investors. Comparatively, 83.7% of Disc Medicine shares are owned by institutional investors. 17.1% of Design Therapeutics shares are owned by company insiders. Comparatively, 3.8% of Disc Medicine shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Disc Medicine is trading at a lower price-to-earnings ratio than Design Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Design Therapeutics	N/A	N/A	-$69.79M	-$1.20	N/A
Disc Medicine	N/A	N/A	-$212.18M	-$6.62	N/A

Design Therapeutics has a beta of 1.63, meaning that its stock price is 63% more volatile than the broader market. Comparatively, Disc Medicine has a beta of 0.93, meaning that its stock price is 7% less volatile than the broader market.

Design Therapeutics' return on equity of -33.07% beat Disc Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Design Therapeutics	N/A	-33.07%	-31.29%
Disc Medicine	N/A	-36.94%	-33.88%

Summary

Design Therapeutics beats Disc Medicine on 10 of the 14 factors compared between the two stocks.

How does Design Therapeutics compare to Anbio Biotechnology?

Anbio Biotechnology (NASDAQ:NNNN) and Design Therapeutics (NASDAQ:DSGN) are both pharmaceutical products companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, institutional ownership, media sentiment, earnings, dividends, analyst recommendations, valuation and profitability.

Design Therapeutics has a consensus price target of $16.50, suggesting a potential upside of 50.41%. Given Design Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Design Therapeutics is more favorable than Anbio Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anbio Biotechnology	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Design Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

Anbio Biotechnology has a beta of 4.4, suggesting that its share price is 340% more volatile than the broader market. Comparatively, Design Therapeutics has a beta of 1.63, suggesting that its share price is 63% more volatile than the broader market.

Anbio Biotechnology's return on equity of 0.00% beat Design Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Anbio Biotechnology	N/A	N/A	N/A
Design Therapeutics	N/A	-33.07%	-31.29%

56.6% of Design Therapeutics shares are held by institutional investors. 17.1% of Design Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, Design Therapeutics had 1 more articles in the media than Anbio Biotechnology. MarketBeat recorded 2 mentions for Design Therapeutics and 1 mentions for Anbio Biotechnology. Anbio Biotechnology's average media sentiment score of 1.89 beat Design Therapeutics' score of 0.94 indicating that Anbio Biotechnology is being referred to more favorably in the media.

Company	Overall Sentiment
Anbio Biotechnology	Very Positive
Design Therapeutics	Positive

Anbio Biotechnology has higher revenue and earnings than Design Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anbio Biotechnology	$8.65M	259.33	$6.40M	N/A	N/A
Design Therapeutics	N/A	N/A	-$69.79M	-$1.20	N/A

Summary

Design Therapeutics beats Anbio Biotechnology on 7 of the 13 factors compared between the two stocks.

How does Design Therapeutics compare to Alumis?

Alumis (NASDAQ:ALMS) and Design Therapeutics (NASDAQ:DSGN) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, earnings, risk, profitability, institutional ownership, dividends and valuation.

In the previous week, Alumis had 1 more articles in the media than Design Therapeutics. MarketBeat recorded 3 mentions for Alumis and 2 mentions for Design Therapeutics. Design Therapeutics' average media sentiment score of 0.94 beat Alumis' score of 0.63 indicating that Design Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alumis	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Design Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

56.6% of Design Therapeutics shares are owned by institutional investors. 33.7% of Alumis shares are owned by insiders. Comparatively, 17.1% of Design Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Alumis has a beta of -0.55, indicating that its stock price is 155% less volatile than the broader market. Comparatively, Design Therapeutics has a beta of 1.63, indicating that its stock price is 63% more volatile than the broader market.

Alumis presently has a consensus price target of $40.30, indicating a potential upside of 66.87%. Design Therapeutics has a consensus price target of $16.50, indicating a potential upside of 50.41%. Given Alumis' higher probable upside, equities analysts plainly believe Alumis is more favorable than Design Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alumis	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.83
Design Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

Design Therapeutics has lower revenue, but higher earnings than Alumis. Alumis is trading at a lower price-to-earnings ratio than Design Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alumis	$24.05M	128.02	-$243.32M	-$1.98	N/A
Design Therapeutics	N/A	N/A	-$69.79M	-$1.20	N/A

Design Therapeutics has a net margin of 0.00% compared to Alumis' net margin of -2,825.70%. Design Therapeutics' return on equity of -33.07% beat Alumis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alumis	-2,825.70%	-88.79%	-70.72%
Design Therapeutics	N/A	-33.07%	-31.29%

Summary

Design Therapeutics beats Alumis on 10 of the 15 factors compared between the two stocks.

Get Design Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DSGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DSGN vs. The Competition

Export

Metric	Design Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$685.15M	$3.40B	$6.74B	$12.07B
Dividend Yield	N/A	2.25%	2.67%	5.67%
P/E Ratio	-9.14	19.82	24.21	24.42
Price / Sales	N/A	305.72	512.05	109.98
Price / Cash	N/A	53.61	27.48	37.92
Price / Book	2.94	8.32	10.66	6.83
Net Income	-$69.79M	$23.94M	$3.57B	$337.67M
7 Day Performance	3.00%	3.53%	0.84%	2.68%
1 Month Performance	-24.55%	-2.55%	-0.34%	1.56%
1 Year Performance	185.68%	44.82%	25.40%	30.59%

Design Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DSGN Design Therapeutics	2.9976 of 5 stars	$10.97 +4.2%	$16.50 +50.4%	+185.7%	$685.15M	N/A	N/A	40
TARS Tarsus Pharmaceuticals	3.5122 of 5 stars	$61.55 +3.2%	$90.67 +47.3%	+51.5%	$2.57B	$451.36M	N/A	50
KLRA Kailera Therapeutics	4.7136 of 5 stars	$19.64 -0.3%	$42.75 +117.7%	N/A	$2.54B	N/A	N/A	145
IRON Disc Medicine	2.1483 of 5 stars	$68.34 +3.9%	$105.30 +54.1%	+26.6%	$2.51B	N/A	N/A	30	News Coverage Analyst Forecast
NNNN Anbio Biotechnology	1.5327 of 5 stars	$16.16 -6.2%	N/A	N/A	$2.48B	$8.65M	N/A	27	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:DSGN) was last updated on 6/14/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Design Therapeutics (DSGN) Competitors

DSGN vs. TARS, KLRA, IRON, NNNN, and ALMS

How does Design Therapeutics compare to Tarsus Pharmaceuticals?

Summary

How does Design Therapeutics compare to Kailera Therapeutics?

Summary

How does Design Therapeutics compare to Disc Medicine?

Summary

How does Design Therapeutics compare to Anbio Biotechnology?

Summary

How does Design Therapeutics compare to Alumis?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DSGN vs. The Competition

Design Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Design Therapeutics (DSGN) Competitors

DSGN vs. TARS, KLRA, IRON, NNNN, and ALMS

How does Design Therapeutics compare to Tarsus Pharmaceuticals?

Do analysts rate TARS or DSGN?

Which has higher earnings and valuation, TARS or DSGN?

Is TARS or DSGN more profitable?

Do insiders & institutionals have more ownership in TARS or DSGN?

Does the media favor TARS or DSGN?

Which has more volatility & risk, TARS or DSGN?

Summary

How does Design Therapeutics compare to Kailera Therapeutics?

Is DSGN or KLRA more profitable?

Do institutionals and insiders have more ownership in DSGN or KLRA?

Does the media favor DSGN or KLRA?

Which has better valuation and earnings, DSGN or KLRA?

Do analysts rate DSGN or KLRA?

Summary

How does Design Therapeutics compare to Disc Medicine?

Do analysts rate DSGN or IRON?

Does the media refer more to DSGN or IRON?

Do insiders & institutionals have more ownership in DSGN or IRON?

Which has stronger valuation and earnings, DSGN or IRON?

Which has more risk & volatility, DSGN or IRON?

Is DSGN or IRON more profitable?

Summary

How does Design Therapeutics compare to Anbio Biotechnology?

Do analysts prefer NNNN or DSGN?

Which has more volatility & risk, NNNN or DSGN?

Is NNNN or DSGN more profitable?

Do institutionals & insiders have more ownership in NNNN or DSGN?

Does the media favor NNNN or DSGN?

Which has preferable earnings & valuation, NNNN or DSGN?

Summary

How does Design Therapeutics compare to Alumis?

Does the media favor ALMS or DSGN?

Do insiders & institutionals believe in ALMS or DSGN?

Which has more volatility and risk, ALMS or DSGN?

Do analysts recommend ALMS or DSGN?

Which has stronger earnings and valuation, ALMS or DSGN?

Is ALMS or DSGN more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DSGN vs. The Competition

Design Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools